Jazz Pharmaceuticals Files Patent Infringement Suit vs. Lupin

July 29, 2021, 10:16 AM

Jazz Pharmaceuticals filed a patent infringement suit against Lupin in the U.S. District Court for the District of New Jersey.

  • The complaint alleges that by Lupin filing its ANDA, the company has infringed ten of the company’s Orange Book listed patents, seeking a permanent injunction to prevent Lupin from introducing a generic version of Xywav
  • Company expects that a stay of approval of up to 30 months will be imposed by FDA on Lupin’s ANDA
    • As recently recognized by FDA, Xywav also has Orphan Drug Exclusivity through July 21, 2027

To view the source of this information click here

To ...

To read the full article log in. To learn more about a subscription click here.